236 related articles for article (PubMed ID: 9745826)
1. [Treatment of glaucoma with carbonic anhydrase inhibitors in eyewash: medium term retrospective experience with dorzolamide].
Detry-Morel M; De Hoste F
Bull Soc Belge Ophtalmol; 1997; 267():157-66. PubMed ID: 9745826
[TBL] [Abstract][Full Text] [Related]
2. Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.
Pajic B;
Curr Med Res Opin; 2003; 19(2):95-101. PubMed ID: 12740152
[TBL] [Abstract][Full Text] [Related]
3. A trial of dorzolamide for glaucoma.
Gillies WE; Brooks AM
Ophthalmic Surg Lasers; 1998 Sep; 29(9):728-32. PubMed ID: 9760608
[TBL] [Abstract][Full Text] [Related]
4. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
Maruyama K; Shirato S
J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
6. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.
Adamsons IA; Polis A; Ostrov CS; Boyle JE
J Glaucoma; 1998 Dec; 7(6):395-401. PubMed ID: 9871861
[TBL] [Abstract][Full Text] [Related]
7. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
Nesher R; Ticho U
Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130
[TBL] [Abstract][Full Text] [Related]
8. Results of the European Glaucoma Prevention Study.
Miglior S; Zeyen T; Pfeiffer N; Cunha-Vaz J; Torri V; Adamsons I;
Ophthalmology; 2005 Mar; 112(3):366-75. PubMed ID: 15745761
[TBL] [Abstract][Full Text] [Related]
9. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices.
Gugleta K; Orgül S; Flammer J
Curr Med Res Opin; 2003; 19(4):330-5. PubMed ID: 12841926
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
12. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
Tamer C; Oksüz H
Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
[TBL] [Abstract][Full Text] [Related]
13. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
14. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
[TBL] [Abstract][Full Text] [Related]
16. Dorzolamide influences the autoregulation of major retinal vessels caused by artificial intraocular pressure elevation in patients with POAG: a clinical study.
Nagel E; Vilser W; Lanzl I
Curr Eye Res; 2005 Feb; 30(2):129-37. PubMed ID: 15814471
[TBL] [Abstract][Full Text] [Related]
17. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.
Portellos M; Buckley EG; Freedman SF
J AAPOS; 1998 Feb; 2(1):43-7. PubMed ID: 10532366
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
Ozturk F; Ermis SS; Inan UU
Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
[TBL] [Abstract][Full Text] [Related]
19. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension.
Gudmundsdóttir E; Stefánsson E; Bjarnadóttir G; Sigurjónsdóttir JF; Gudmundsdóttir G; Masson M; Loftsson T
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3552-4. PubMed ID: 11006251
[TBL] [Abstract][Full Text] [Related]
20. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
Martínez A; Sánchez M
Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
